• Disclosure
  • Privacy Policy
  • DMCA Policy
  • CCPA
  • Medical Disclaimer
Sunday, February 5, 2023
Salt Lake City News Now
  • Home
  • News
  • Business
  • Technology
    • Crytpocurrency
    • Gaming
    • Gadgets
  • Sports
  • Health
  • General
    • Business Services
  • Travel
  • Press Releases
  • Popular
No Result
View All Result
  • Home
  • News
  • Business
  • Technology
    • Crytpocurrency
    • Gaming
    • Gadgets
  • Sports
  • Health
  • General
    • Business Services
  • Travel
  • Press Releases
  • Popular
No Result
View All Result
No Result
View All Result
Home News

Officials Outline Tight Deadline If U.S. Wants To Redesign Vaccines Before Fall – The New York Times

officials-outline-tight-deadline-if-us.-wants-to-redesign-vaccines-before-fall-–-the-new-york-times
Share on FacebookShare on Twitter

Politics|Officials outline a tight deadline if the U.S. wants to redesign its Covid vaccines before the fall.

https://www.nytimes.com/2022/04/06/us/politics/fda-covid-boosters.html

Outside experts are exploring the need to reconfigure vaccines in order to better protect the United States against new variants.
Outside experts are exploring the need to reconfigure vaccines in order to better protect the United States against new variants.Credit…Charles Krupa/Associated Press

Sharon LaFraniere

  • April 6, 2022Updated 4:03 p.m. ET

A top federal health official outlined a tight time frame on Wednesday if the Biden administration hopes to have new coronavirus vaccines by the fall that better meet the threat of a fast-evolving virus, saying clinical trials would have to be underway by next month in order to produce the shots.

Robert Johnson, the director of an infectious disease division within the Department of Health and Human Services, said vaccine manufacturers would need several months to produce hundreds of millions of doses of a reconfigured vaccine.

“If you’re not on your way to that clinical trial by the beginning of May, it is very difficult to have collectively across manufacturers enough product to meet that demand,” he told a meeting of an expert advisory committee to the Food and Drug Administration. Dr. Peter Marks, who oversees vaccine regulation for the F.D.A., also said the time frame was tightly compressed, with a possible decision needed by May or June.

The panel of outside experts is grappling with what the U.S. coronavirus vaccine strategy should be for the rest of the year, amid growing evidence that new variants have eroded some of the existing vaccines’ power.

The meeting, which can be watched live on YouTube, represents a kind of transition point for the federal governments. In their presentations, the experts outlined a landscape studded with uncertainties, starting with the basic question of how to modify the existing vaccines so they work better.

A number of clinical studies are already underway, conducted both at the National Institutes of Health and by vaccine manufacturers themselves. The trials are too small to give efficacy data of the type that first led to the authorization of the existing vaccines. But they could produce enough immune response data for federal health officials to determine whether a retooled vaccine will work better than current ones.

Expert after expert described how much guesswork is involved in trying to design a better vaccine at this point. No one knows which variant of the virus will dominate in the fall, when some consider a new surge highly likely. There is some chance another variant like Omicron will emerge that redraws the coronavirus picture in a wholly unexpected way — a factor that can be neither measured nor discounted.

Trevor Bedford, a biostatistician at the Fred Hutchinson Cancer Research Center, said the coronavirus has been mutating at a pace that far exceeds that of the flu virus, for which vaccines are redesigned annually. While that pace may slow, the virus’s plasticity to date indicates it “is likely to keep on evolving,” he said.

Dr. John Beigel, a clinical research director at N.I.H, described a new study designed to compare how well Moderna’s existing vaccine works compared to modified versions aimed at the known variants, both alone and in combination. In an interview Tuesday, he said the existing vaccines might still turn out to be the best.

In the first stage, researchers are hoping to rapidly enroll 600 volunteers who have already been vaccinated and received a booster. Some will be given the existing vaccine. Others will get experimental vaccines targeted to Omicron variant alone as well as three other variations: Omicron plus the Beta variant, the Delta variant and the prototype virus that emerged first in the pandemic.

Dr. Beigel said that he hopes results may be ready by midsummer, although some federal officials are hoping for earlier.

Panelists also heard from Sharon Alroy-Preis, the director of public health services for Israel’s Health Ministry, who described Israel’s experience with administering a second booster for those ages 60 and older earlier this year.

Relying heavily on Israeli data, the F.D.A. last week authorized a second booster for Americans 50 and older, among other groups. The C.D.C. director, has recommended those shots for those 65 and older, and anyone ages 50 to 64 with serious underlying health conditions.

Some immunologists and vaccine experts, including at least one member of the F.D.A.’s expert panel, have said the federal government went too far with too little data.

Dr. James E. K. Hildreth, president of the Meharry Medical College in Tennessee, pointedly asked why the F.D.A. had convened the panel to discuss future vaccine policy but did not solicit its advice before deciding whether to authorize a second booster.

Dr. Marks said that the agency did not consider offering a second booster to be “a major expansion or a major change.” Jerry Weir, another senior agency official, said the F.D.A. expects to ask the advisory panel to review any reconfiguration of the existing vaccines before moving forward with emergency authorization.

Salt Lake City News Now

© 2021 Salt Lake City News Now

Navigate Site

  • Disclosure
  • Privacy Policy
  • DMCA Policy
  • CCPA
  • Medical Disclaimer

Follow Us

No Result
View All Result
  • Home
  • DMCA Policy
  • Medical Disclaimer
  • Privacy Policy
  • Disclosure
  • CCPA
  • Terms of Use

© 2021 Salt Lake City News Now

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
Cookie SettingsAccept All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT